News

Conference Coverage

Ibrutinib Plus Venetoclax Demonstrates Efficacy, Safety for TP53-Mutated Mantle Cell Lymphoma Treatment

06/28/2024

At the 2024 ASCO Annual Meeting, Michael Wang, MD, presents data from the SYMPATICO trail on the encouraging efficacy and safety of ibrutinib plus venetoclax for patients with high-risk TP53-mutated mantle cell lymphoma.

At the 2024 ASCO Annual Meeting,...

06/28/2024

Oncology

FDA Approval

FDA Approves Lisocabtagene Maraleucel for Patients With R/R Mantle Cell Lymphoma

06/03/2024

Amber Denham

The U.S. Food and Drug Administration granted approval to lisocabtagene maraleucel for adult patients with relapsed or refractory MCL who have received at least 2 prior lines of systemic therapy including a BTK inhibitor.

The U.S. Food and Drug...

06/03/2024

Oncology

News

Rituximab Maintenance After ASCT Yields Long-Term Benefits for Patients With Mantle Cell Lymphoma

03/05/2024

Jordan Kadish

According to a long-term follow-up of the LYMA trial, rituximab maintenance following autologous stem cell transplantation continued to demonstrate benefits to efficacy and safety outcomes among first-line patients with mantle cell lymphoma.

According to a long-term...

03/05/2024

Oncology

News

Novel Prognostic Models Provide Valuable Guidance for Mantle Cell Lymphoma Treatment Strategy

03/01/2024

Jordan Kadish

Advances in prognostic models can help guide treatment strategy for patients with mantle cell lymphoma, according to an analysis by The North American Mantle Cell Lymphoma Consortium.

Advances in prognostic models...

03/01/2024

Oncology

News

BTK Inhibitor and T-Cell Redirecting Immunotherapy Combination Shows Promise for Patients With R/R MCL

02/28/2024

Amber Denham

According to a phase 2 study, the combination of time-limited ibrutinib and T-cell redirecting immunotherapy demonstrates promising results among patients with relapsed/refractory mantle cell lymphoma.

According to a phase 2 study,...

02/28/2024

Oncology

News

MRD-Driven Venetoclax, Lenalidomide, and Rituximab Combo Demonstrates Efficacy Among Patients With R/R Mantle Cell Lymphoma

02/23/2024

Amber Denham

Minimal residual disease-driven venetoclax, lenalidomide, and rituximab is a feasible and tolerable treatment regimen for patients with relapsed/refractory mantle cell lymphoma, according to results from a phase 1b/2 study.

Minimal residual disease-driven...

02/23/2024

Oncology

Conference Coverage

Assessing Efficacy of Acalabrutinib-Rituximab Followed by Chemo and ASCT for Patients With Treatment-Naive MCL

02/13/2024

Featuring Eliza A Hawkes, MD

Eliza A Hawkes, MD, shares findings from the phase 2 WAMM trial, which assessed the use of acalabrutinib-rituximab followed by chemotherapy and autologous stem cell transplantation among young and fit patients with treatment-naive MCL.

Eliza A Hawkes, MD, shares...

02/13/2024

Oncology

News

MRD Status Predicts Efficacy of Rituximab Maintenance Among Elderly Patients With MCL

01/24/2024

Jordan Kadish

Minimal residual disease status held value in predicting the efficacy of rituximab maintenance among elderly patients with previously untreated mantle cell lymphoma.

Minimal residual disease status...

01/24/2024

Oncology

Conference Coverage

Examining Efficacy of Frontline Bendamustine-Rituximab and Second-Line BTK Inhibitor Therapy Among Patients With MCL

01/10/2024

Featuring Yucai Wang, MD, PhD

At the 65th ASH Annual Meeting, Yucai Wang, MD, PhD, discusses trial findings that first-line bendamustine-rituximab and second-line Bruton’s tyrosine kinase inhibitor therapy yielded efficacious outcomes among patients with mantle cell...

At the 65th ASH Annual Meeting,...

01/10/2024

Oncology

Conference Coverage

Recent Breakthroughs in the Mantle Cell Lymphoma Treatment Landscape

01/08/2024

Featuring Bijal D. Shah, MD

Bijal D. Shah, MD, shares the breakthroughs in the mantle cell lymphoma treatment landscape that he found most promising at the 65th American Society of Hematology (ASH) Annual Meeting.

Bijal D. Shah, MD, shares the...

01/08/2024

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology